Workflow
Gene - editing
icon
Search documents
4 Healthcare Stocks to Buy Now
The Motley Fool· 2025-10-12 13:45
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research pipelines advanced. Many promising companies now trade at a fraction of their previous highs, while investors pour money into artificial intelligence (AI) names trading at record multiples.That gap ...
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead
Yahoo Finance· 2025-10-08 14:15
Key Points CRISPR Therapeutics and BioNTech have climbed along with many of their peers over the past week. Both are innovative biotechs with catalysts that could drive their stocks higher in the next few years. 10 stocks we like better than CRISPR Therapeutics › On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices of certain drugs in the U.S. and investin ...
1 Stock Up by 63% This Year That Could Double, According to Wall Street
Yahoo Finance· 2025-10-07 13:45
Intellia is collaborating with Regeneron Pharmaceuticals , a leading biotech company, to develop nex-z. This therapy targets transthyretin (ATTR) amyloidosis, a disease caused by the buildup of abnormal transthyretin proteins in the heart, which can lead to heart problems or other issues. ATTR amyloidosis can either be hereditary or acquired with age. Intellia is conducting a phase 3 study for nex-z in ATTR amyloidosis with cardiomyopathy (a condition in which the heart has difficulty pumping blood), as wel ...
AstraZeneca signs up to $555 million AI deal with Algen to develop therapies
Yahoo Finance· 2025-10-06 12:04
(Reuters) -Algen Biotechnologies said on Monday it had agreed to grant AstraZeneca a license to develop therapies the U.S.-based biotech discover using its AI-driven gene-editing platform, in a deal worth up to $555 million. AstraZeneca will get exclusive rights to develop and sell approved therapies, if any, that target immune system-related disorders in exchange for upfront and milestone payments to Algen. AstraZeneca has been advancing its cell and gene therapy capabilities through acquisitions and pa ...
Could This Beaten-Down Stock Help You Become a Millionaire?
Yahoo Finance· 2025-09-30 14:00
Key Points CRISPR Therapeutics has a couple of pipeline candidates with massive opportunities. The company has already shown that it can get approval for its gene-editing medicines. Despte sizable upside potential for the stock, investors should proceed with caution. 10 stocks we like better than CRISPR Therapeutics › Becoming a millionaire through stock investing is possible, but it requires patience, discipline, and the acumen to make informed investment choices. Not every company can generate ...
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
ZACKS· 2025-08-12 16:41
Core Insights - CRISPR Therapeutics' Casgevy, a one-shot gene therapy, received approval in late 2023 and early 2024 for sickle cell disease and transfusion-dependent beta-thalassemia in the US and Europe [1] - The partnership with Vertex Pharmaceuticals involves a 60:40 split of program costs and profits, with Vertex leading global development and commercialization [1] Sales Performance - Casgevy had a slow start in 2024, generating only $10 million in full-year product revenues for Vertex, but sales increased significantly to $30.4 million in Q2 2025, marking a 114.1% sequential increase [2][8] - Vertex estimates Casgevy sales to reach approximately $124.6 million in 2025 [2] Treatment Centers and Patient Engagement - Over 75 authorized treatment centers are active for Casgevy, with 115 patients completing their first cell collection as of June 2025 [3][8] Revenue Growth Potential - Increasing Casgevy sales could provide a stable revenue base for CRISPR Therapeutics, allowing for greater investment in its gene-editing pipeline and enhancing long-term growth prospects in the competitive cell and gene therapy market [4][8] Competitive Landscape - Other companies in the gene-editing space include Beam Therapeutics, which is developing BEAM-101 for sickle cell disease, and Intellia Therapeutics, which is advancing in vivo therapies for hereditary angioedema and transthyretin amyloidosis [5][6] Stock Performance and Valuation - CRISPR Therapeutics' shares have increased by 40.7% year-to-date, contrasting with a 0.7% decline in the industry [7] - The company's shares trade at a price-to-book value (P/B) ratio of 2.80, below the industry average of 3.15, but above its five-year mean of 2.38 [9] Earnings Estimates - Loss per share estimates for CRISPR Therapeutics for 2025 have widened from $5.58 to $6.22, while estimates for 2026 have narrowed from $4.30 to $4.03 [10]
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
Globenewswire· 2025-06-26 20:30
Core Points - Cellectis held a shareholders general meeting on June 26, 2025, where approximately 57% of voting rights were exercised, resulting in the adoption of resolutions 1 through 23 and resolutions 25 and 26, while resolution 24 was rejected [2] - Mr. André Muller was appointed to the Board of Directors, while Mr. Axel-Sven Malkomes' term expired and Mr. Pierre Bastid's resignation became effective [3][4] - The Chairman of the Board, Jean-Pierre Garnier, expressed gratitude for the contributions of the departing directors and highlighted Mr. Muller's extensive experience as an asset to the company [5] Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using a pioneering gene-editing platform [6] - The company specializes in an allogeneic approach for CAR T immunotherapies in oncology, aiming to provide off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [6] - Cellectis maintains in-house manufacturing capabilities, positioning itself as one of the few end-to-end gene editing companies that control the entire cell and gene therapy value chain [6][7]
Crispr Therapeutics: Betting On A One-Shot Future
Seeking Alpha· 2025-06-13 22:27
Core Insights - The article discusses Crispr Therapeutics AG's diversified gene-editing pipeline and highlights a strong cash position of $2.1 billion, which supports its ongoing projects [1]. Group 1 - The company has a diversified gene-editing pipeline that is crucial for its growth and innovation in the biotech sector [1]. - The strong cash position of $2.1 billion provides a solid financial foundation for the company's research and development efforts [1].
2 Beaten-Down Stocks With Incredible Upside Potential
The Motley Fool· 2025-04-30 09:14
Group 1: Iovance Biotherapeutics - Iovance Biotherapeutics specializes in cancer treatment and received approval for Amtagvi, a therapy for advanced melanoma, which is the first of its kind for solid tumors [3][4] - The company generated $164.1 million in revenue last year, a significant increase from the previous year when it had minimal revenue [4] - Despite the approval and revenue growth, the stock has underperformed due to market dynamics and the complexity of administering TIL therapies, which take 34 days to manufacture [5] - The stock is currently priced under $4 per share, and the company is pursuing regulatory approvals and label expansions for Amtagvi, which could lead to significant upside potential [6] Group 2: CRISPR Therapeutics - CRISPR Therapeutics develops gene-editing therapies using the CRISPR/Cas9 technique and received approval for Casgevy, the first CRISPR medicine, which treats rare blood disorders [8] - The company has not generated substantial revenue since the approval, as manufacturing ex vivo gene-editing therapies is complex and time-consuming [9] - Casgevy is priced at $2.2 million in the U.S., targeting a market of approximately 58,000 patients with minimal competition, indicating potential for significant revenue once it gains traction [10] - The company has delivered returns comparable to the broader market since its IPO in 2016, and long-term investors may benefit from future breakthroughs in gene-editing products [11][13]